NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
16.63
-0.06 (-0.36%)
Sep 21, 2026, 10:07 AM EDT - Market open
NovoCure Revenue
NovoCure had revenue of $183.58M in the quarter ending June 30, 2026, with 15.60% growth. This brings the company's revenue in the last twelve months to $699.19M, up 10.95% year-over-year. In the year 2025, NovoCure had annual revenue of $655.35M with 8.28% growth.
Revenue (ttm)
$699.19M
Revenue Growth
+10.95%
P/S Ratio
2.78
Revenue / Employee
$435,634
Employees
1,605
Market Cap
1.94B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 655.35M | 50.13M | 8.28% |
| Dec 31, 2024 | 605.22M | 95.88M | 18.82% |
| Dec 31, 2023 | 509.34M | -28.50M | -5.30% |
| Dec 31, 2022 | 537.84M | 2.81M | 0.53% |
| Dec 31, 2021 | 535.03M | 40.67M | 8.23% |
| Dec 31, 2020 | 494.37M | 143.05M | 40.72% |
| Dec 31, 2019 | 351.32M | 103.25M | 41.62% |
| Dec 31, 2018 | 248.07M | 71.04M | 40.13% |
| Dec 31, 2017 | 177.03M | 94.14M | 113.57% |
| Dec 31, 2016 | 82.89M | 49.80M | 150.52% |
| Dec 31, 2015 | 33.09M | 17.60M | 113.60% |
| Dec 31, 2014 | 15.49M | 5.13M | 49.53% |
| Dec 31, 2013 | 10.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Integra LifeSciences Holdings | 1.65B |
| CONMED | 1.37B |
| Inspire Medical Systems | 898.74M |
| Neogen | 870.40M |
| Alphatec Holdings | 815.05M |
| TransMedics Group | 668.47M |
| UFP Technologies | 631.64M |
| Axogen | 251.17M |
NVCR News
- 6 days ago - NovoCure Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 12 days ago - NovoCure Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 19 days ago - Novocure Announces Upcoming Investor Events - Business Wire
- 20 days ago - Oncology firm Novocure says cyberattack exposed US patient records - Reuters
- 20 days ago - Novocure aware of unauthorized access to some information systems - TheFly
- 1 month ago - Novocure price target raised to $20 from $18 at Wedbush - TheFly
- 1 month ago - Novocure price target raised to $52 from $46 at H.C. Wainwright - TheFly
- 2 months ago - NovoCure Earnings Call Transcript: Q2 2026 - Transcripts